NewsBenzingaGoodfellow Q3 EPS $0.27 Down From $0.44 YoY, Sales $145.719M Up From $141.910M YoY Goodfellow Q3 EPS $0.27 Down From $0.44 YoY, Sales $145.719M Up From $141.910M YoY Benzinga 2026.10.06 21:19 (GMT+0) Open on Benzinga Other news Biohaven's Phase 1 Data Presented In Oral Plenary Session At ENA 2026 Shows Deep, Durable Responses In Patients With FGFR3-Altered Urothelial Cancer And Head And Neck Squamous Cell Carcinoma Clearmind Medicine Publishes Hong Kong Patent Application Covering Innovative Psychedelic Compounds Targeting Treatment Of PTSD And Other Mental Health Disorders Freedom Capital Markets Maintains Hold on Bullish, Lowers Price Target to $23 Warner Music Gr Q4 Adj. EPS $0.55 Beats $0.36 Estimate, Sales $2.001B Beat $1.906B Estimate Biohaven Presents Clinical Data From Ongoing Phase 1 Study Of BHV-1530, Potential FGFR3-Directed ADC With Topoisomerase I Payload, At ENA 2026 Bernstein Maintains Outperform on Agilon Health, Raises Price Target to $138
Biohaven's Phase 1 Data Presented In Oral Plenary Session At ENA 2026 Shows Deep, Durable Responses In Patients With FGFR3-Altered Urothelial Cancer And Head And Neck Squamous Cell Carcinoma
Clearmind Medicine Publishes Hong Kong Patent Application Covering Innovative Psychedelic Compounds Targeting Treatment Of PTSD And Other Mental Health Disorders
Biohaven Presents Clinical Data From Ongoing Phase 1 Study Of BHV-1530, Potential FGFR3-Directed ADC With Topoisomerase I Payload, At ENA 2026